Equities research analysts predict that Axsome Therapeutics Inc (NASDAQ:AXSM) will announce ($0.41) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Axsome Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.39). Axsome Therapeutics reported earnings per share of ($0.31) in the same quarter last year, which would indicate a negative year over year growth rate of 32.3%. The company is expected to issue its next quarterly earnings results on Friday, November 8th.
On average, analysts expect that Axsome Therapeutics will report full year earnings of ($1.40) per share for the current year, with EPS estimates ranging from ($1.54) to ($1.17). For the next financial year, analysts forecast that the firm will report earnings of ($1.30) per share, with EPS estimates ranging from ($1.72) to ($0.85). Zacks’ EPS averages are a mean average based on a survey of research firms that follow Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10).
Several brokerages have commented on AXSM. BidaskClub downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, June 12th. Zacks Investment Research upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 23rd. HC Wainwright set a $30.00 price objective on shares of Axsome Therapeutics and gave the company a “buy” rating in a research report on Monday, June 24th. ValuEngine downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, SunTrust Banks began coverage on shares of Axsome Therapeutics in a research report on Tuesday, May 28th. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Axsome Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $30.83.
In related news, Director Mark E. Saad purchased 3,500 shares of the stock in a transaction dated Thursday, May 23rd. The stock was bought at an average cost of $22.33 per share, for a total transaction of $78,155.00. Following the completion of the acquisition, the director now owns 7,002 shares of the company’s stock, valued at $156,354.66. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Nick Pizzie purchased 1,920 shares of the stock in a transaction dated Tuesday, June 11th. The shares were bought at an average price of $20.80 per share, with a total value of $39,936.00. Following the completion of the acquisition, the chief financial officer now directly owns 1,920 shares of the company’s stock, valued at approximately $39,936. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 5,820 shares of company stock valued at $127,391. Company insiders own 27.50% of the company’s stock.
Large investors have recently made changes to their positions in the company. Bank of Montreal Can acquired a new position in shares of Axsome Therapeutics during the second quarter worth $52,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Axsome Therapeutics in the second quarter worth $72,000. Schroder Investment Management Group bought a new stake in shares of Axsome Therapeutics in the second quarter worth $76,000. Focused Wealth Management Inc bought a new stake in shares of Axsome Therapeutics in the first quarter worth $64,000. Finally, SG Americas Securities LLC bought a new stake in shares of Axsome Therapeutics in the second quarter worth $167,000. Institutional investors own 45.10% of the company’s stock.
AXSM traded up $2.23 during trading on Tuesday, hitting $27.64. 852,320 shares of the stock traded hands, compared to its average volume of 1,690,860. Axsome Therapeutics has a twelve month low of $1.94 and a twelve month high of $28.70. The firm has a market cap of $874.61 million, a P/E ratio of -24.03 and a beta of 2.64. The company has a debt-to-equity ratio of 1.08, a quick ratio of 5.68 and a current ratio of 5.68. The business’s 50 day moving average is $25.89.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Featured Story: What are the benefits of buying treasury bonds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.